D
Ligand Pharmaceuticals Incorporated
LGND
$104.27
$2.982.94%
D
Sell
3/12/2025Downgrade
Ligand Pharmaceuticals Incorporated (LGND) was downgraded to D from D+ on 3/12/2025 due to a decline in the total return index.
Ligand Pharmaceuticals Incorporated (LGND) was downgraded to D from D+ on 3/12/2025 due to a decline in the total return index.
D
Sell
3/3/2025Downgrade
Ligand Pharmaceuticals Incorporated (LGND) was downgraded to D+ from C on 3/3/2025 due to a significant decline in the growth index, valuation index and efficiency index. Net income declined 333.46% from -$7.17M to -$31.09M, earnings per share declined from -$0.39 to -$1.6413, and EBIT declined 84.6% from $10.96M to $1.69M.
Ligand Pharmaceuticals Incorporated (LGND) was downgraded to D+ from C on 3/3/2025 due to a significant decline in the growth index, valuation index and efficiency index. Net income declined 333.46% from -$7.17M to -$31.09M, earnings per share declined from -$0.39 to -$1.6413, and EBIT declined 84.6% from $10.96M to $1.69M.
C
Hold
11/11/2024Upgraded
Ligand Pharmaceuticals Incorporated (LGND) was upgraded to C from C- on 11/11/2024 due to a significant increase in the growth index, total return index and solvency index. Operating cash flow increased 174.37% from $13.31M to $36.53M, earnings per share increased from -$2.88 to -$0.39, and EBIT increased 48.22% from $7.39M to $10.96M.
Ligand Pharmaceuticals Incorporated (LGND) was upgraded to C from C- on 11/11/2024 due to a significant increase in the growth index, total return index and solvency index. Operating cash flow increased 174.37% from $13.31M to $36.53M, earnings per share increased from -$2.88 to -$0.39, and EBIT increased 48.22% from $7.39M to $10.96M.
C
Hold
8/8/2024Downgrade
Ligand Pharmaceuticals Incorporated (LGND) was downgraded to C- from C on 8/8/2024 due to a significant decline in the valuation index, efficiency index and growth index. Earnings per share declined from $4.75 to -$2.88, net income declined 160.26% from $86.14M to -$51.91M, and operating cash flow declined 28.92% from $18.73M to $13.31M.
Ligand Pharmaceuticals Incorporated (LGND) was downgraded to C- from C on 8/8/2024 due to a significant decline in the valuation index, efficiency index and growth index. Earnings per share declined from $4.75 to -$2.88, net income declined 160.26% from $86.14M to -$51.91M, and operating cash flow declined 28.92% from $18.73M to $13.31M.
C
Hold
5/14/2024Upgraded
Ligand Pharmaceuticals Incorporated (LGND) was upgraded to C from D+ on 5/14/2024 due to a major increase in the valuation index, efficiency index and volatility index. Net income increased 373.6% from $18.19M to $86.14M, and total capital increased 14.94% from $707.1M to $812.72M.
Ligand Pharmaceuticals Incorporated (LGND) was upgraded to C from D+ on 5/14/2024 due to a major increase in the valuation index, efficiency index and volatility index. Net income increased 373.6% from $18.19M to $86.14M, and total capital increased 14.94% from $707.1M to $812.72M.
D
Sell
4/25/2024Downgrade
Ligand Pharmaceuticals Incorporated (LGND) was downgraded to D+ from C- on 4/25/2024 due to a decline in the volatility index and valuation index.
Ligand Pharmaceuticals Incorporated (LGND) was downgraded to D+ from C- on 4/25/2024 due to a decline in the volatility index and valuation index.
C
Hold
4/4/2024Upgraded
Ligand Pharmaceuticals Incorporated (LGND) was upgraded to C- from D+ on 4/4/2024 due to an increase in the volatility index, valuation index and total return index.
Ligand Pharmaceuticals Incorporated (LGND) was upgraded to C- from D+ on 4/4/2024 due to an increase in the volatility index, valuation index and total return index.
D
Sell
3/1/2024Upgraded
Ligand Pharmaceuticals Incorporated (LGND) was upgraded to D+ from D on 3/1/2024 due to a major increase in the valuation index, total return index and efficiency index. Net income increased 277.05% from -$10.27M to $18.19M, and total capital increased 4.88% from $674.23M to $707.1M.
Ligand Pharmaceuticals Incorporated (LGND) was upgraded to D+ from D on 3/1/2024 due to a major increase in the valuation index, total return index and efficiency index. Net income increased 277.05% from -$10.27M to $18.19M, and total capital increased 4.88% from $674.23M to $707.1M.
D
Sell
11/13/2023Downgrade
Ligand Pharmaceuticals Incorporated (LGND) was downgraded to D from D+ on 11/13/2023 due to a noticeable decline in the efficiency index, growth index and valuation index. Earnings per share declined from $0.13 to -$0.5911, net income declined 548.6% from $2.29M to -$10.27M, and total capital declined 0.35% from $676.56M to $674.23M.
Ligand Pharmaceuticals Incorporated (LGND) was downgraded to D from D+ on 11/13/2023 due to a noticeable decline in the efficiency index, growth index and valuation index. Earnings per share declined from $0.13 to -$0.5911, net income declined 548.6% from $2.29M to -$10.27M, and total capital declined 0.35% from $676.56M to $674.23M.
D
Sell
5/17/2023Upgraded
Ligand Pharmaceuticals Incorporated (LGND) was upgraded to D+ from D on 5/17/2023 due to a noticeable increase in the efficiency index, growth index and valuation index. Net income increased 339.91% from -$17.49M to $41.95M, earnings per share increased from -$1.0352 to $2.3374, and EBIT increased 170.68% from -$20.1M to $14.21M.
Ligand Pharmaceuticals Incorporated (LGND) was upgraded to D+ from D on 5/17/2023 due to a noticeable increase in the efficiency index, growth index and valuation index. Net income increased 339.91% from -$17.49M to $41.95M, earnings per share increased from -$1.0352 to $2.3374, and EBIT increased 170.68% from -$20.1M to $14.21M.
D
Sell
5/12/2022Downgrade
Ligand Pharmaceuticals Incorporated (LGND) was downgraded to D from D+ on 5/12/2022 due to a decline in the volatility index and total return index.
Ligand Pharmaceuticals Incorporated (LGND) was downgraded to D from D+ on 5/12/2022 due to a decline in the volatility index and total return index.
D
Sell
5/10/2022Downgrade
Ligand Pharmaceuticals Incorporated (LGND) was downgraded to D+ from C- on 5/10/2022 due to a large decline in the valuation index, efficiency index and volatility index. Net income declined 184.07% from -$5.42M to -$15.39M, and total capital declined 14.76% from $1.16B to $988.43M.
Ligand Pharmaceuticals Incorporated (LGND) was downgraded to D+ from C- on 5/10/2022 due to a large decline in the valuation index, efficiency index and volatility index. Net income declined 184.07% from -$5.42M to -$15.39M, and total capital declined 14.76% from $1.16B to $988.43M.
C
Hold
3/15/2022Downgrade
Ligand Pharmaceuticals Incorporated (LGND) was downgraded to C- from C on 3/15/2022 due to a significant decline in the growth index and total return index. Earnings per share declined from $0.8 to -$0.3273.
Ligand Pharmaceuticals Incorporated (LGND) was downgraded to C- from C on 3/15/2022 due to a significant decline in the growth index and total return index. Earnings per share declined from $0.8 to -$0.3273.
C
Hold
5/10/2021Upgraded
Ligand Pharmaceuticals Incorporated (LGND) was upgraded to C from D+ on 5/10/2021 due to a significant increase in the growth index, total return index and efficiency index. Operating cash flow increased 1,902.61% from $537 to $10.75M, net income increased 214.29% from $5.76M to $18.11M, and earnings per share increased from $0.3504 to $1.05.
Ligand Pharmaceuticals Incorporated (LGND) was upgraded to C from D+ on 5/10/2021 due to a significant increase in the growth index, total return index and efficiency index. Operating cash flow increased 1,902.61% from $537 to $10.75M, net income increased 214.29% from $5.76M to $18.11M, and earnings per share increased from $0.3504 to $1.05.
D
Sell
2/2/2021Upgraded
Ligand Pharmaceuticals Incorporated (LGND) was upgraded to D+ from D on 2/2/2021 due to an increase in the volatility index, solvency index and efficiency index. Total capital increased 0.19% from $1.16B to $1.16B.
Ligand Pharmaceuticals Incorporated (LGND) was upgraded to D+ from D on 2/2/2021 due to an increase in the volatility index, solvency index and efficiency index. Total capital increased 0.19% from $1.16B to $1.16B.
D
Sell
10/21/2020Downgrade
Ligand Pharmaceuticals Incorporated (LGND) was downgraded to D from D+ on 10/21/2020 due to a decline in the volatility index, total return index and valuation index.
Ligand Pharmaceuticals Incorporated (LGND) was downgraded to D from D+ on 10/21/2020 due to a decline in the volatility index, total return index and valuation index.
D
Sell
8/7/2020Upgraded
Ligand Pharmaceuticals Incorporated (LGND) was upgraded to D+ from D on 8/7/2020 due to a noticeable increase in the total return index, volatility index and solvency index.
Ligand Pharmaceuticals Incorporated (LGND) was upgraded to D+ from D on 8/7/2020 due to a noticeable increase in the total return index, volatility index and solvency index.
D
Sell
5/8/2020Downgrade
Ligand Pharmaceuticals Incorporated (LGND) was downgraded to D from D+ on 5/8/2020 due to a significant decline in the valuation index, efficiency index and growth index. Earnings per share declined from -$0.4326 to -$1.46, net income declined 227.64% from -$7.37M to -$24.13M, and total capital declined 21.19% from $1.42B to $1.12B.
Ligand Pharmaceuticals Incorporated (LGND) was downgraded to D from D+ on 5/8/2020 due to a significant decline in the valuation index, efficiency index and growth index. Earnings per share declined from -$0.4326 to -$1.46, net income declined 227.64% from -$7.37M to -$24.13M, and total capital declined 21.19% from $1.42B to $1.12B.
D
Sell
5/1/2020Downgrade
Ligand Pharmaceuticals Incorporated (LGND) was downgraded to D+ from C- on 5/1/2020 due to a decline in the volatility index and valuation index.
Ligand Pharmaceuticals Incorporated (LGND) was downgraded to D+ from C- on 5/1/2020 due to a decline in the volatility index and valuation index.
C
Hold
4/15/2020Upgraded
Ligand Pharmaceuticals Incorporated (LGND) was upgraded to C- from D+ on 4/15/2020 due to an increase in the volatility index.
Ligand Pharmaceuticals Incorporated (LGND) was upgraded to C- from D+ on 4/15/2020 due to an increase in the volatility index.
D
Sell
3/26/2020Downgrade
Ligand Pharmaceuticals Incorporated (LGND) was downgraded to D+ from C- on 3/26/2020 due to a noticeable decline in the growth index, total return index and volatility index. EBIT declined 45% from -$5.16M to -$7.48M, and operating cash flow declined 18.43% from -$6.2M to -$7.34M.
Ligand Pharmaceuticals Incorporated (LGND) was downgraded to D+ from C- on 3/26/2020 due to a noticeable decline in the growth index, total return index and volatility index. EBIT declined 45% from -$5.16M to -$7.48M, and operating cash flow declined 18.43% from -$6.2M to -$7.34M.
C
Hold
1/8/2020Downgrade
Ligand Pharmaceuticals Incorporated (LGND) was downgraded to C- from C on 1/8/2020 due to a decline in the volatility index and efficiency index.
Ligand Pharmaceuticals Incorporated (LGND) was downgraded to C- from C on 1/8/2020 due to a decline in the volatility index and efficiency index.
C
Hold
12/4/2019Upgraded
Ligand Pharmaceuticals Incorporated (LGND) was upgraded to C from C- on 12/4/2019 due to an increase in the total return index.
Ligand Pharmaceuticals Incorporated (LGND) was upgraded to C from C- on 12/4/2019 due to an increase in the total return index.
C
Hold
11/19/2019Downgrade
Ligand Pharmaceuticals Incorporated (LGND) was downgraded to C- from C on 11/19/2019 due to a decline in the solvency index, volatility index and efficiency index. Debt to equity increased from 0.63 to 0.74, total capital declined 12.4% from $1.7B to $1.49B, and net income declined 5.77% from -$14.42M to -$15.25M.
Ligand Pharmaceuticals Incorporated (LGND) was downgraded to C- from C on 11/19/2019 due to a decline in the solvency index, volatility index and efficiency index. Debt to equity increased from 0.63 to 0.74, total capital declined 12.4% from $1.7B to $1.49B, and net income declined 5.77% from -$14.42M to -$15.25M.
C
Hold
10/29/2019Upgraded
Ligand Pharmaceuticals Incorporated (LGND) was upgraded to C from C- on 10/29/2019 due to an increase in the volatility index.
Ligand Pharmaceuticals Incorporated (LGND) was upgraded to C from C- on 10/29/2019 due to an increase in the volatility index.
C
Hold
10/2/2019Downgrade
Ligand Pharmaceuticals Incorporated (LGND) was downgraded to C- from C on 10/2/2019 due to a decline in the total return index, volatility index and valuation index.
Ligand Pharmaceuticals Incorporated (LGND) was downgraded to C- from C on 10/2/2019 due to a decline in the total return index, volatility index and valuation index.
C
Hold
9/10/2019Upgraded
Ligand Pharmaceuticals Incorporated (LGND) was upgraded to C from C- on 9/10/2019 due to an increase in the volatility index and valuation index.
Ligand Pharmaceuticals Incorporated (LGND) was upgraded to C from C- on 9/10/2019 due to an increase in the volatility index and valuation index.
C
Hold
7/31/2019Downgrade
Ligand Pharmaceuticals Incorporated (LGND) was downgraded to C- from C on 7/31/2019 due to a major decline in the total return index and volatility index.
Ligand Pharmaceuticals Incorporated (LGND) was downgraded to C- from C on 7/31/2019 due to a major decline in the total return index and volatility index.
C
Hold
1/14/2019Downgrade
Ligand Pharmaceuticals Incorporated (LGND) was downgraded to C from C+ on 1/14/2019 due to a decline in the volatility index and valuation index.
Ligand Pharmaceuticals Incorporated (LGND) was downgraded to C from C+ on 1/14/2019 due to a decline in the volatility index and valuation index.
C
Hold
12/28/2018Upgraded
Ligand Pharmaceuticals Incorporated (LGND) was upgraded to C+ from C on 12/28/2018 due to an increase in the valuation index.
Ligand Pharmaceuticals Incorporated (LGND) was upgraded to C+ from C on 12/28/2018 due to an increase in the valuation index.
C
Hold
12/13/2018Downgrade
Ligand Pharmaceuticals Incorporated (LGND) was downgraded to C from C+ on 12/13/2018 due to a noticeable decline in the total return index, volatility index and solvency index.
Ligand Pharmaceuticals Incorporated (LGND) was downgraded to C from C+ on 12/13/2018 due to a noticeable decline in the total return index, volatility index and solvency index.
C
Hold
11/19/2018Downgrade
Ligand Pharmaceuticals Incorporated (LGND) was downgraded to C+ from B- on 11/19/2018 due to a decline in the total return index and volatility index.
Ligand Pharmaceuticals Incorporated (LGND) was downgraded to C+ from B- on 11/19/2018 due to a decline in the total return index and volatility index.
B
Buy
11/14/2018Downgrade
Ligand Pharmaceuticals Incorporated (LGND) was downgraded to B- from B on 11/14/2018 due to a significant decline in the growth index, total return index and volatility index. EBIT declined 66.71% from $70.18M to $23.36M, operating cash flow declined 63.23% from $73.64M to $27.08M, and total revenue declined 49.29% from $90.04M to $45.66M.
Ligand Pharmaceuticals Incorporated (LGND) was downgraded to B- from B on 11/14/2018 due to a significant decline in the growth index, total return index and volatility index. EBIT declined 66.71% from $70.18M to $23.36M, operating cash flow declined 63.23% from $73.64M to $27.08M, and total revenue declined 49.29% from $90.04M to $45.66M.
B
Buy
8/14/2018Upgraded
Ligand Pharmaceuticals Incorporated (LGND) was upgraded to B from C+ on 8/14/2018 due to a significant increase in the growth index, valuation index and volatility index. EBIT increased 89.45% from $37.04M to $70.18M, earnings per share increased from $1.83 to $2.99, and total revenue increased 60.34% from $56.16M to $90.04M.
Ligand Pharmaceuticals Incorporated (LGND) was upgraded to B from C+ on 8/14/2018 due to a significant increase in the growth index, valuation index and volatility index. EBIT increased 89.45% from $37.04M to $70.18M, earnings per share increased from $1.83 to $2.99, and total revenue increased 60.34% from $56.16M to $90.04M.
C
Hold
5/11/2018Upgraded
Ligand Pharmaceuticals Incorporated (LGND) was upgraded to C+ from C on 5/11/2018 due to a significant increase in the growth index, total return index and efficiency index. Net income increased 745.92% from -$7.01M to $45.28M, earnings per share increased from -$0.3361 to $1.83, and operating cash flow increased 94.06% from $31.31M to $60.76M.
Ligand Pharmaceuticals Incorporated (LGND) was upgraded to C+ from C on 5/11/2018 due to a significant increase in the growth index, total return index and efficiency index. Net income increased 745.92% from -$7.01M to $45.28M, earnings per share increased from -$0.3361 to $1.83, and operating cash flow increased 94.06% from $31.31M to $60.76M.
C
Hold
3/12/2018Downgrade
Ligand Pharmaceuticals Incorporated (LGND) was downgraded to C from B- on 3/12/2018 due to a significant decline in the growth index, efficiency index and total return index. Earnings per share declined from $0.36 to -$0.3361, net income declined 183.19% from $8.43M to -$7.01M, and total capital declined 0.49% from $646.32M to $643.18M.
Ligand Pharmaceuticals Incorporated (LGND) was downgraded to C from B- on 3/12/2018 due to a significant decline in the growth index, efficiency index and total return index. Earnings per share declined from $0.36 to -$0.3361, net income declined 183.19% from $8.43M to -$7.01M, and total capital declined 0.49% from $646.32M to $643.18M.
B
Buy
1/19/2018Downgrade
Ligand Pharmaceuticals Incorporated (LGND) was downgraded to B- from B on 1/19/2018 due to a decline in the total return index, valuation index and volatility index.
Ligand Pharmaceuticals Incorporated (LGND) was downgraded to B- from B on 1/19/2018 due to a decline in the total return index, valuation index and volatility index.
B
Buy
1/4/2018Upgraded
Ligand Pharmaceuticals Incorporated (LGND) was upgraded to B from B- on 1/4/2018 due to an increase in the total return index and volatility index.
Ligand Pharmaceuticals Incorporated (LGND) was upgraded to B from B- on 1/4/2018 due to an increase in the total return index and volatility index.
B
Buy
12/1/2017Downgrade
Ligand Pharmaceuticals Incorporated (LGND) was downgraded to B- from B on 12/1/2017 due to a noticeable decline in the total return index and volatility index.
Ligand Pharmaceuticals Incorporated (LGND) was downgraded to B- from B on 12/1/2017 due to a noticeable decline in the total return index and volatility index.
B
Buy
11/13/2017Upgraded
Ligand Pharmaceuticals Incorporated (LGND) was upgraded to B from C+ on 11/13/2017 due to a substantial increase in the growth index, total return index and solvency index. Operating cash flow increased 166.22% from $10.39M to $27.65M, earnings per share increased from $0.26 to $0.36, and EBIT increased 26.72% from $13.02M to $16.49M.
Ligand Pharmaceuticals Incorporated (LGND) was upgraded to B from C+ on 11/13/2017 due to a substantial increase in the growth index, total return index and solvency index. Operating cash flow increased 166.22% from $10.39M to $27.65M, earnings per share increased from $0.26 to $0.36, and EBIT increased 26.72% from $13.02M to $16.49M.
C
Hold
10/5/2017Upgraded
Ligand Pharmaceuticals Incorporated (LGND) was upgraded to C+ from C on 10/5/2017 due to a major increase in the total return index and volatility index.
Ligand Pharmaceuticals Incorporated (LGND) was upgraded to C+ from C on 10/5/2017 due to a major increase in the total return index and volatility index.
C
Hold
8/11/2017Upgraded
Ligand Pharmaceuticals Incorporated (LGND) was upgraded to C from C- on 8/11/2017 due to a significant increase in the growth index, volatility index and efficiency index. EBIT increased 27.4% from $10.22M to $13.02M, net income increased 19.28% from $5.08M to $6.06M, and earnings per share increased from $0.22 to $0.26.
Ligand Pharmaceuticals Incorporated (LGND) was upgraded to C from C- on 8/11/2017 due to a significant increase in the growth index, volatility index and efficiency index. EBIT increased 27.4% from $10.22M to $13.02M, net income increased 19.28% from $5.08M to $6.06M, and earnings per share increased from $0.22 to $0.26.
C
Hold
3/3/2017Downgrade
Ligand Pharmaceuticals Incorporated (LGND) was downgraded to C- from C on 3/3/2017 due to a large decline in the growth index and efficiency index. Earnings per share declined from $0.05 to -$0.1496, and net income declined 397.43% from $1.05M to -$3.13M.
Ligand Pharmaceuticals Incorporated (LGND) was downgraded to C- from C on 3/3/2017 due to a large decline in the growth index and efficiency index. Earnings per share declined from $0.05 to -$0.1496, and net income declined 397.43% from $1.05M to -$3.13M.
C
Hold
2/8/2017Upgraded
Ligand Pharmaceuticals Incorporated (LGND) was upgraded to C from C- on 2/8/2017 due to an increase in the total return index.
Ligand Pharmaceuticals Incorporated (LGND) was upgraded to C from C- on 2/8/2017 due to an increase in the total return index.
C
Hold
11/17/2016Downgrade
Ligand Pharmaceuticals Incorporated (LGND) was downgraded to C- from C+ on 11/17/2016 due to a significant decline in the valuation index, growth index and efficiency index.
Ligand Pharmaceuticals Incorporated (LGND) was downgraded to C- from C+ on 11/17/2016 due to a significant decline in the valuation index, growth index and efficiency index.
C
Hold
11/4/2016Downgrade
Ligand Pharmaceuticals Incorporated (LGND) was downgraded to C+ from B- on 11/4/2016 due to a major decline in the total return index and volatility index.
Ligand Pharmaceuticals Incorporated (LGND) was downgraded to C+ from B- on 11/4/2016 due to a major decline in the total return index and volatility index.
B
Buy
8/17/2016Downgrade
Ligand Pharmaceuticals Incorporated (LGND) was downgraded to B- from B on 8/17/2016 due to a large decline in the total return index, growth index and efficiency index. Earnings per share declined from $0.2928 to -$0.28, net income declined 187.21% from $6.61M to -$5.76M, and EBIT declined 69.04% from $15.34M to $4.75M.
Ligand Pharmaceuticals Incorporated (LGND) was downgraded to B- from B on 8/17/2016 due to a large decline in the total return index, growth index and efficiency index. Earnings per share declined from $0.2928 to -$0.28, net income declined 187.21% from $6.61M to -$5.76M, and EBIT declined 69.04% from $15.34M to $4.75M.
B
Buy
3/29/2016Upgraded
Ligand Pharmaceuticals Incorporated (LGND) was upgraded to B from B- on 3/29/2016 due to a large increase in the total return index and volatility index.
Ligand Pharmaceuticals Incorporated (LGND) was upgraded to B from B- on 3/29/2016 due to a large increase in the total return index and volatility index.
B
Buy
3/14/2016Downgrade
Ligand Pharmaceuticals Incorporated (LGND) was downgraded to B- from B on 3/14/2016 due to a decline in the total return index and valuation index.
Ligand Pharmaceuticals Incorporated (LGND) was downgraded to B- from B on 3/14/2016 due to a decline in the total return index and valuation index.
B
Buy
3/11/2016Downgrade
Ligand Pharmaceuticals Incorporated (LGND) was downgraded to B from A on 3/11/2016 due to a significant decline in the volatility index and growth index. Earnings per share declined from $10.46 to $0.393.
Ligand Pharmaceuticals Incorporated (LGND) was downgraded to B from A on 3/11/2016 due to a significant decline in the volatility index and growth index. Earnings per share declined from $10.46 to $0.393.
A
Buy
1/7/2016Upgraded
Ligand Pharmaceuticals Incorporated (LGND) was upgraded to A from A- on 1/7/2016 due to an increase in the solvency index and total return index.
Ligand Pharmaceuticals Incorporated (LGND) was upgraded to A from A- on 1/7/2016 due to an increase in the solvency index and total return index.
A
Buy
11/13/2015Upgraded
Ligand Pharmaceuticals Incorporated (LGND) was upgraded to A- from B on 11/13/2015 due to a significant increase in the valuation index, solvency index and efficiency index. Net income increased 852.89% from $23.56M to $224.54M, total capital increased 83.64% from $269.62M to $495.13M, and debt to equity declined from 2.9 to 0.69.
Ligand Pharmaceuticals Incorporated (LGND) was upgraded to A- from B on 11/13/2015 due to a significant increase in the valuation index, solvency index and efficiency index. Net income increased 852.89% from $23.56M to $224.54M, total capital increased 83.64% from $269.62M to $495.13M, and debt to equity declined from 2.9 to 0.69.
B
Buy
8/25/2015Downgrade
Ligand Pharmaceuticals Incorporated (LGND) was downgraded to B from B+ on 8/25/2015 due to a large decline in the total return index.
Ligand Pharmaceuticals Incorporated (LGND) was downgraded to B from B+ on 8/25/2015 due to a large decline in the total return index.
B
Buy
8/10/2015Upgraded
Ligand Pharmaceuticals Incorporated (LGND) was upgraded to B+ from B on 8/10/2015 due to an increase in the valuation index.
Ligand Pharmaceuticals Incorporated (LGND) was upgraded to B+ from B on 8/10/2015 due to an increase in the valuation index.
B
Buy
8/7/2015Upgraded
Ligand Pharmaceuticals Incorporated (LGND) was upgraded to B from C on 8/7/2015 due to a significant increase in the growth index, total return index and valuation index. Earnings per share increased from $0.0384 to $1.11, operating cash flow increased 32.55% from $7.58M to $10.05M, and EBIT increased 28.3% from $3.57M to $4.58M.
Ligand Pharmaceuticals Incorporated (LGND) was upgraded to B from C on 8/7/2015 due to a significant increase in the growth index, total return index and valuation index. Earnings per share increased from $0.0384 to $1.11, operating cash flow increased 32.55% from $7.58M to $10.05M, and EBIT increased 28.3% from $3.57M to $4.58M.
C
Hold
6/18/2014Downgrade
Ligand Pharmaceuticals Incorporated (LGND) was downgraded to C from C+ on 6/18/2014 due to a decline in the total return index and valuation index.
Ligand Pharmaceuticals Incorporated (LGND) was downgraded to C from C+ on 6/18/2014 due to a decline in the total return index and valuation index.
C
Hold
5/9/2014Upgraded
Ligand Pharmaceuticals Incorporated (LGND) was upgraded to C+ from C on 5/9/2014 due to a large increase in the solvency index, growth index and valuation index. The quick ratio increased from 0.78 to 1.47, debt to equity declined from 0.18 to 0.09, and earnings per share increased from $0.0914 to $0.1.
Ligand Pharmaceuticals Incorporated (LGND) was upgraded to C+ from C on 5/9/2014 due to a large increase in the solvency index, growth index and valuation index. The quick ratio increased from 0.78 to 1.47, debt to equity declined from 0.18 to 0.09, and earnings per share increased from $0.0914 to $0.1.
C
Hold
4/21/2014Downgrade
Ligand Pharmaceuticals Incorporated (LGND) was downgraded to C from C+ on 4/21/2014 due to a large decline in the total return index.
Ligand Pharmaceuticals Incorporated (LGND) was downgraded to C from C+ on 4/21/2014 due to a large decline in the total return index.
C
Hold
3/20/2014Upgraded
Ligand Pharmaceuticals Incorporated (LGND) was upgraded to C+ from C on 3/20/2014 due to a large increase in the total return index, growth index and solvency index. EBIT increased 100.97% from $3.3M to $6.63M, the quick ratio increased from 0.41 to 0.78, and debt to equity declined from 0.28 to 0.18.
Ligand Pharmaceuticals Incorporated (LGND) was upgraded to C+ from C on 3/20/2014 due to a large increase in the total return index, growth index and solvency index. EBIT increased 100.97% from $3.3M to $6.63M, the quick ratio increased from 0.41 to 0.78, and debt to equity declined from 0.28 to 0.18.
NASDAQ
04/11/2025 4:00PM Eastern
Quotes delayed
